According to a study where TRC105 was combined with bevacizumab, several patients who had previously progressed on anti-VEGF therapies experienced reductions in tumor volume or remained progression-free for a longer period than on bevacizumab alone. This evidence concerns the gene VEGFA and neoplasm.